Ipsen S.A. (EPA:IPN)

Market Cap	13.15B +58.1%
Revenue (ttm)	3.93B +9.9%
Net Income	443.50M +28.2%
EPS	5.32 +28.2%
Shares Out	82.10M
PE Ratio	30.11
Forward PE	11.80
Dividend	1.40 (0.87%)
Ex-Dividend Date	Jun 3, 2026

Volume	95,635
Average Volume	110,553
Open	161.10
Previous Close	160.60
Day's Range	159.50 - 163.40
52-Week Range	100.00 - 173.50
Beta	0.33
RSI	46.04
Earnings Date	Jul 30, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1929
• Employees: 5,535
• Stock Exchange: Euronext Paris
• Ticker Symbol: IPN

Financial Performance

In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.